MARKET

PVLA

PVLA

Palvella Therapeutics Inc
NASDAQ
114.29
-1.63
-1.41%
Opening 15:17 05/22 EDT
OPEN
116.78
PREV CLOSE
115.92
HIGH
117.25
LOW
113.10
VOLUME
97.37K
TURNOVER
--
52 WEEK HIGH
151.18
52 WEEK LOW
20.20
MARKET CAP
1.64B
P/E (TTM)
-27.4868
1D
5D
1M
3M
1Y
5Y
1D
Buy Rating Reiterated on Palvella as QTORIN Data Strengthen and $227 Price Target Remains Unchanged
TipRanks · 7h ago
Fein Reiterates Buy on PVLA, Maintains $270 Price Target on Strong QTORIN Rapamycin Data and Clear Regulatory Path
TipRanks · 1d ago
Palvella Therapeutics Price Target Maintained With a $220.00/Share by Stephens & Co.
Dow Jones · 1d ago
Stephens & Co. Reiterates Overweight on Palvella Therapeutics, Maintains $220 Price Target
Benzinga · 1d ago
Palvella Therapeutics Is Maintained at Buy by Chardan Capital
Dow Jones · 1d ago
Palvella Therapeutics Price Target Maintained With a $240.00/Share by Chardan Capital
Dow Jones · 1d ago
Analysts Offer Insights on Healthcare Companies: Dyne Therapeutics (DYN) and Palvella Therapeutics (PVLA)
TipRanks · 1d ago
Oppenheimer Remains a Buy on Palvella Therapeutics (PVLA)
TipRanks · 1d ago
More
About PVLA
Palvella Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing therapies to treat patients suffering from serious, rare genetic skin diseases for which there are no FDA-approved therapies. The Company is developing a pipeline of product candidates based on its patented QTORIN platform, with an initial focus on serious, rare genetic skin diseases, many of which are lifelong in nature. Its QTORIN product candidates are developed to accommodate the cargo at high concentrations in order to drive sufficient drug to its target deep in the epidermis and dermis. The Company's lead product candidate, QTORIN 3.9% rapamycin anhydrous gel (QTORIN rapamycin), is being evaluated in the Phase III SELVA clinical trial in microcystic lymphatic malformations and the Phase II TOIVA clinical trial in cutaneous venous malformations.

Webull offers Palvella Therapeutics Inc stock information, including NASDAQ: PVLA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, PVLA stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading PVLA stock methods without spending real money on the virtual paper trading platform.